Neoantigen-loaded DC vaccine

The Neoantigen-loaded DC vaccine is an investigational autologous cell therapy being developed by The First Affiliated Hospital of Nanchang University for the treatment of colorectal cancer. This personalized immunotherapy involves harvesting a patient's own dendritic cells (DCs) and loading them with tumor-specific neoantigens identified through genomic sequencing of the patient's tumor tissue. These neoantigens represent mutations unique to the individual's cancer, which are not present in healthy cells. Once administered, the vaccine is designed to present these neoantigens to the patient's T cells, thereby priming and activating a targeted immune response against the tumor. In clinical settings, this vaccine is often evaluated in combination with conventional second-line therapies, including chemotherapy and PD-1 inhibitors, to overcome immune evasion and improve outcomes in patients who have progressed after initial treatment.

Other names

Personalized tumor neoantigen-loaded DC vaccineNeoantigen-loaded dendritic cell vaccinePersonalized tumor neoantigen-loaded dendritic cell vaccine